Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Dextenza
Punctal_Plug_Technology |
| gptkbp:CEO |
George_Elston
|
| gptkbp:clinicalTrials |
Phase 1
Phase 2 Phase 3 Macular degeneration Uveitis Post-surgical pain Dextenza for dry eye disease Dextenza_for_allergic_conjunctivitis Dextenza_for_cataract_surgery Dextenza_for_corneal_surgery Dextenza_for_ocular_surgery Dextenza_for_post-surgical_pain EYP-1901_for_age-related_macular_degeneration EYP-1901_for_diabetic_retinopathy EYP-1901_for_glaucoma EYP-1901_for_retinal_vein_occlusion EYP-1901_for_wet_AMD Yutiq_for_chronic_non-infectious_uveitis Yutiq_for_ocular_inflammation Yutiq_for_post-operative_pain Yutiq_for_retinal_diseases Yutiq_for_uveitic_macular_edema |
| gptkbp:collaborations |
gptkb:University_of_Massachusetts
|
| gptkbp:focus |
Ocular therapeutics
|
| gptkbp:founded |
1998
|
| gptkbp:founder |
gptkb:Nancy_L._McKinney
|
| gptkbp:headquarters |
gptkb:Watertown,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
EyePoint Pharmaceuticals
|
| gptkbp:investmentFocus |
$50 million (2021)
|
| gptkbp:market |
$200 million (2021)
|
| gptkbp:partnerships |
gptkb:Pfizer
gptkb:Aerie_Pharmaceuticals gptkb:Santen_Pharmaceutical gptkb:Bausch_+_Lomb Novartis |
| gptkbp:patentCitation |
Ocular drug delivery system
Sustained-release formulation |
| gptkbp:patentType |
Dextenza
Yutiq |
| gptkbp:products |
Dextenza
EYP-1901 Yutiq |
| gptkbp:research_focus |
Sustained-release drug delivery systems
|
| gptkbp:revenue |
$20 million (2020)
|
| gptkbp:sells |
EYPT
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:technology |
gptkb:BioSilicon
Sustained-release implants |